| 11.7 -0.19 (-1.6%) | 10-07 09:38 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 15.9  |
1-year : | 17.26 |
| Resists | First : | 13.61 |
Second : | 14.77 |
| Pivot price | 13.12 |
|||
| Supports | First : | 11.73 |
Second : | 9.76 |
| MAs | MA(5) : | 12.48 |
MA(20) : | 13.31 |
| MA(100) : | 14.69 |
MA(250) : | 12.66  |
|
| MACD | MACD : | -0.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 6.5 |
D(3) : | 7 |
| RSI | RSI(14): 24 |
|||
| 52-week | High : | 17.39 | Low : | 7.13 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BWAY ] has closed below the lower bollinger band by 8.1%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 1.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.38 - 12.5 | 12.5 - 12.57 |
| Low: | 11.49 - 11.64 | 11.64 - 11.74 |
| Close: | 11.71 - 11.96 | 11.96 - 12.11 |
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Sat, 03 Oct 2026
Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Stock Has Average Price Target of $18.20 - MarketBeat
Fri, 02 Oct 2026
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable - Eastern Progress
Tue, 22 Sep 2026
BrainsWay: Execution Isn’t The Problem, Market Size Is (NASDAQ:BWAY) - Seeking Alpha
Thu, 10 Sep 2026
BrainsWay’s (BWAY) Growth Streak Just Got Harder To Ignore - Yahoo Finance
Tue, 08 Sep 2026
New brain stimulation study from BrainsWay (NASDAQ: BWAY) eases depression in patients with early Alzheimer’s - Stock Titan
Thu, 27 Aug 2026
After six weeks, 70% fewer patients showed suicidal thoughts in a BrainsWay study - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 40 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 32.4 (%) |
| Shares Short | 156 (K) |
| Shares Short P.Month | 172 (K) |
| EPS | 0.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.04 |
| Profit Margin | 15.5 % |
| Operating Margin | 13.9 % |
| Return on Assets (ttm) | 4 % |
| Return on Equity (ttm) | 12.8 % |
| Qtrly Rev. Growth | 35.4 % |
| Gross Profit (p.s.) | 1.13 |
| Sales Per Share | 1.5 |
| EBITDA (p.s.) | 0.21 |
| Qtrly Earnings Growth | 64.5 % |
| Operating Cash Flow | 8 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | 51.69 |
| PEG Ratio | 0 |
| Price to Book value | 5.8 |
| Price to Sales | 7.87 |
| Price to Cash Flow | 63.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|